HMS
CLDX icon

Hanseatic Management Services’s Celldex Therapeutics CLDX Stock Holding History

Hanseatic Management Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,340
Closed -$72K – 148
2021
Q3 		$72K Buy
+1,340
New +$62.9K 0.12% 64
2015
Q3 		– Sell
-820
Closed -$310K – 373
2015
Q2 		$310K Buy
820
+37
+5% +$14.7K 0.14% 164
2015
Q1 		$328K Hold
783
– – 0.18% 143
2014
Q4 		$214K Buy
+783
New +$195K 0.11% 144

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hanseatic Management Services's CLDX Position: Q4 2021 in Review

Hanseatic Management Services sold out of Celldex Therapeutics (CLDX) in Q4 2021, closing a stake of 1,340 shares — an estimated $72K sold.

Hanseatic Management Services first reported a position in CLDX in Q4 2014 and held it in 4 quarters. The position peaked at $328K in Q1 2015. 180 funds tracked by Wall St. Rank hold CLDX as of Q4 2021.

  • Hanseatic Management Services reported no remaining Celldex Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Hanseatic Management Services sold 1,340 Celldex Therapeutics shares in Q4 2021, an estimated $72K.
  • Hanseatic Management Services first reported a position in Celldex Therapeutics in Q4 2014 and held it in 4 quarters.
  • Hanseatic Management Services's Celldex Therapeutics position peaked at $328K in Q1 2015.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2021.

Based on Hanseatic Management Services's 13F filing for Q4 2021, filed 9 Feb 2022.